Pharma Missing Out From Market Access Challenges In China: EU Group

Politicized Environment 'Alarming'

Slower approvals for foreign drugs, a volume-based procurement scheme and localization requirements caused nearly 80% of respondent European pharma firms to miss out on opportunities in China, where they also continue to decouple from headquarters in a “in China-for-China” strategy, a survey from a prominent EU business group shows.

EU CHAMBER IN CHINA BUSINESS CLIMATE SURVEY 2021
EU PHARMA MISSES OUT IN CHINA DUE TO ACCESS BARRIERS, SURVEY SHOWS • Source: European Chamber of Commerce in China

Despite China notably accelerating new drug reviews and approvals, the government is giving priority to domestically developed innovative drugs, causing many foreign companies to cry foul of an uneven playground, a newly released business climate survey shows.

The survey, conducted in February of its 538 member companies by the EU Chamber of Commerce in China (EUCCC), was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

More from Focus On Asia

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By 

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.